HRP20141258T1 - 6-amino-2-{[(1s)-1-metilbutil]oksi}-9-[5-(1-piperidinil)pentil]-7,9-dihidro-8h-purin-8-on maleat - Google Patents

6-amino-2-{[(1s)-1-metilbutil]oksi}-9-[5-(1-piperidinil)pentil]-7,9-dihidro-8h-purin-8-on maleat Download PDF

Info

Publication number
HRP20141258T1
HRP20141258T1 HRP20141258AT HRP20141258T HRP20141258T1 HR P20141258 T1 HRP20141258 T1 HR P20141258T1 HR P20141258A T HRP20141258A T HR P20141258AT HR P20141258 T HRP20141258 T HR P20141258T HR P20141258 T1 HRP20141258 T1 HR P20141258T1
Authority
HR
Croatia
Prior art keywords
compound
methylbutyl
piperidinyl
dihydro
oxy
Prior art date
Application number
HRP20141258AT
Other languages
English (en)
Croatian (hr)
Inventor
Robert Hermann Gibbon
Amanda Lucas
Stephen Andrew Hermitage
Original Assignee
Glaxosmithkline Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Llc filed Critical Glaxosmithkline Llc
Publication of HRP20141258T1 publication Critical patent/HRP20141258T1/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/18—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 one oxygen and one nitrogen atom, e.g. guanine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Otolaryngology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Saccharide Compounds (AREA)
HRP20141258AT 2010-02-10 2011-02-08 6-amino-2-{[(1s)-1-metilbutil]oksi}-9-[5-(1-piperidinil)pentil]-7,9-dihidro-8h-purin-8-on maleat HRP20141258T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US30301010P 2010-02-10 2010-02-10
PCT/EP2011/051830 WO2011098452A1 (en) 2010-02-10 2011-02-08 6-amino-2-{ [ (1s)-1-methylbutyl] oxy}-9-[5-(1-piperidinyl)-7,9-dihydro-8h-purin-8-one maleate
EP11709025.8A EP2534149B1 (en) 2010-02-10 2011-02-08 6-amino-2-{[(1s)-1-methylbutyl]oxy}-9-[5-(1-piperidinyl)pentyl]-7,9-dihydro-8h-purin-8-one maleate

Publications (1)

Publication Number Publication Date
HRP20141258T1 true HRP20141258T1 (hr) 2015-02-27

Family

ID=43836817

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20141258AT HRP20141258T1 (hr) 2010-02-10 2011-02-08 6-amino-2-{[(1s)-1-metilbutil]oksi}-9-[5-(1-piperidinil)pentil]-7,9-dihidro-8h-purin-8-on maleat

Country Status (23)

Country Link
US (1) US8703754B2 (enExample)
EP (1) EP2534149B1 (enExample)
JP (1) JP5922587B2 (enExample)
KR (1) KR101773541B1 (enExample)
CN (1) CN102753553B (enExample)
AU (1) AU2011214468B2 (enExample)
BR (1) BR112012018904A2 (enExample)
CA (1) CA2786973C (enExample)
DK (1) DK2534149T3 (enExample)
EA (1) EA021048B1 (enExample)
ES (1) ES2525826T3 (enExample)
HR (1) HRP20141258T1 (enExample)
IL (1) IL220845A (enExample)
ME (1) ME01926B (enExample)
MX (1) MX2012009316A (enExample)
PL (1) PL2534149T3 (enExample)
PT (1) PT2534149E (enExample)
RS (1) RS53745B1 (enExample)
SG (1) SG182471A1 (enExample)
SI (1) SI2534149T1 (enExample)
SM (1) SMT201400196B (enExample)
WO (1) WO2011098452A1 (enExample)
ZA (1) ZA201205995B (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA103195C2 (uk) 2008-08-11 2013-09-25 Глаксосмитклайн Ллк Похідні пурину для застосування у лікуванні алергій, запальних та інфекційних захворювань
SG171914A1 (en) 2008-12-02 2011-07-28 Chiralgen Ltd Method for the synthesis of phosphorus atom modified nucleic acids
US9744183B2 (en) 2009-07-06 2017-08-29 Wave Life Sciences Ltd. Nucleic acid prodrugs and methods of use thereof
NO2491035T3 (enExample) 2009-10-22 2018-01-27
DK2620428T3 (da) 2010-09-24 2019-07-01 Wave Life Sciences Ltd Asymmetrisk hjælpegruppe
RU2014105311A (ru) 2011-07-19 2015-08-27 Уэйв Лайф Сайенсес Пте. Лтд. Способы синтеза функционализованных нуклеиновых кислот
AU2012289042A1 (en) * 2011-07-22 2014-03-13 Glaxosmithkline Llc Composition
BR112015000723A2 (pt) * 2012-07-13 2017-06-27 Shin Nippon Biomedical Laboratories Ltd adjuvante de ácido nucléico quiral
KR102712879B1 (ko) 2012-07-13 2024-10-04 웨이브 라이프 사이언시스 리미티드 키랄 제어
PT2872485T (pt) 2012-07-13 2021-03-05 Wave Life Sciences Ltd Grupo auxiliar assimétrico
UA114109C2 (xx) 2012-08-24 2017-04-25 Піразолопіримідинові сполуки
US9550785B2 (en) 2012-11-20 2017-01-24 Glaxosmithkline Llc Pyrrolopyrimidines as therapeutic agents for the treatment of diseases
ES2625023T3 (es) 2012-11-20 2017-07-18 Glaxosmithkline Llc Compuestos novedosos
US9540383B2 (en) 2012-11-20 2017-01-10 Glaxosmithkline Llc Pyrrolopyrimidines as therapeutic agents for the treatment of diseases
JPWO2015108047A1 (ja) 2014-01-15 2017-03-23 株式会社新日本科学 免疫誘導活性を有するキラル核酸アジュバンド及び免疫誘導活性剤
JPWO2015108046A1 (ja) 2014-01-15 2017-03-23 株式会社新日本科学 抗アレルギー作用を有するキラル核酸アジュバンド及び抗アレルギー剤
JPWO2015108048A1 (ja) 2014-01-15 2017-03-23 株式会社新日本科学 抗腫瘍作用を有するキラル核酸アジュバンド及び抗腫瘍剤
PT3094728T (pt) 2014-01-16 2022-05-19 Wave Life Sciences Ltd Desenho quiral
ES2944885T3 (es) * 2014-08-29 2023-06-26 Corium Pharma Solutions Inc Matriz de microestructuras para administración de agentes activos
CN107108628A (zh) * 2014-11-13 2017-08-29 葛兰素史密丝克莱恩生物有限公司 可用于治疗变应性疾病或其它炎性病症的腺嘌呤衍生物
US12130267B2 (en) * 2018-11-28 2024-10-29 Shimadzu Corporation Analyzing method for azo compound
KR20250106231A (ko) 2023-12-29 2025-07-09 (주)셀트리온 안정한 약제학적 제제

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB427857A (en) 1934-08-02 1935-05-01 Newsum Sons & Company Ltd H A new or improved system of construction for skeleton structures, particularly vehicle body frames and door frames
US5569450A (en) 1993-03-17 1996-10-29 Minnesota Mining And Manufacturing Company Aerosol formulation containing an ester-, amide-, or mercaptoester-derived dispersing aid
US6126919A (en) 1997-02-07 2000-10-03 3M Innovative Properties Company Biocompatible compounds for pharmaceutical drug delivery systems
EP1065213A3 (en) 1999-07-02 2003-11-05 Japan Tobacco Inc. HCV polymerase suitable for crystal structure analysis and method for using the enzyme
IL145071A0 (en) 1999-12-27 2002-06-30 Japan Tobacco Inc Fused ring compounds and pharmaceutical compositions containing the same
US6448281B1 (en) 2000-07-06 2002-09-10 Boehringer Ingelheim (Canada) Ltd. Viral polymerase inhibitors
US6310224B1 (en) 2001-01-19 2001-10-30 Arco Chemical Technology, L.P. Epoxidation catalyst and process
CN1267446C (zh) 2001-01-22 2006-08-02 默克公司 作为依赖于rna的rna病毒聚合酶的抑制剂的核苷衍生物
KR20030093248A (ko) 2001-03-19 2003-12-06 오노 야꾸힝 고교 가부시키가이샤 트리아자스피로[5.5]운데칸 유도체를 유효성분으로서함유하는 약제
AR035543A1 (es) 2001-06-26 2004-06-16 Japan Tobacco Inc Agente terapeutico para la hepatitis c que comprende un compuesto de anillo condensado, compuesto de anillo condensado, composicion farmaceutica que lo comprende, compuestos de benzimidazol, tiazol y bifenilo utiles como intermediarios para producir dichos compuestos, uso del compuesto de anillo con
US6841566B2 (en) 2001-07-20 2005-01-11 Boehringer Ingelheim, Ltd. Viral polymerase inhibitors
CA2481502A1 (en) 2002-04-04 2003-10-16 Achillion Pharmaceuticals, Inc. Hcv antiviral and cytotoxicity drug screening assay
DOP2003000641A (es) 2002-05-10 2003-11-15 Pfizer Inhibidores de las arn polimerasa dependiente de arn del virus de las hepatitis c y composiciones y tratamiento que los usan
AR041816A1 (es) 2002-10-24 2005-06-01 Glaxo Group Ltd Compuesto de acil-pirrolidina, su uso para preparar una composicion farmaceutica, composicion farmaceutica que lo comprende y procedimiento para prepararlo
WO2004055011A1 (en) 2002-12-13 2004-07-01 Smithkline Beecham Corporation Heterocyclic compounds as ccr5 antagonists
CN1744899A (zh) 2002-12-13 2006-03-08 史密丝克莱恩比彻姆公司 作为ccr5拮抗剂的哌啶衍生物
DE60322423D1 (de) 2002-12-13 2008-09-04 Smithkline Beecham Corp Pyrrolidin- und azetidinverbindungen alsccr5-antagonisten
US7531661B2 (en) 2002-12-13 2009-05-12 Smithkline Beecham Corporation Indane compounds as CCR5 antagonists
AU2003297048A1 (en) 2002-12-13 2004-07-09 Smithkline Beecham Corporation Cyclohexyl compounds as ccr5 antagonists
ATE384724T1 (de) 2002-12-13 2008-02-15 Smithkline Beecham Corp Cyclopropylverbindungen als ccr5 antagonisten
US7223785B2 (en) 2003-01-22 2007-05-29 Boehringer Ingelheim International Gmbh Viral polymerase inhibitors
US7098231B2 (en) 2003-01-22 2006-08-29 Boehringer Ingelheim International Gmbh Viral polymerase inhibitors
US7148226B2 (en) 2003-02-21 2006-12-12 Agouron Pharmaceuticals, Inc. Inhibitors of hepatitis C virus RNA-dependent RNA polymerase, and compositions and treatments using the same
WO2005014543A1 (ja) 2003-08-06 2005-02-17 Japan Tobacco Inc. 縮合環化合物及びそのｈｃｖポリメラーゼ阻害剤としての利用
PL1699512T3 (pl) 2003-11-03 2012-11-30 Glaxo Group Ltd Urządzenie do dozowania płynów
ES2431314T3 (es) 2004-02-20 2013-11-26 Boehringer Ingelheim International Gmbh Inhibidores de polimerasa vírica
KR20070011501A (ko) 2004-04-28 2007-01-24 애로우 쎄라퓨틱스 리미티드 항바이러스제로서 유용한 모르폴리닐아닐리노퀴나졸린유도체
US7153848B2 (en) 2004-08-09 2006-12-26 Bristol-Myers Squibb Company Inhibitors of HCV replication
EA012605B1 (ru) 2004-08-18 2009-10-30 Пфайзер Инк. Ингибиторы рнк-зависимой рнк-полимеразы вируса гепатита с и композиции и способы лечения с их использованием
WO2006026394A2 (en) 2004-08-27 2006-03-09 3M Innovative Properties Company Method of eliciting an immune response against hiv
GB0423673D0 (en) 2004-10-25 2004-11-24 Glaxo Group Ltd Compounds
NZ563866A (en) 2005-05-09 2011-03-31 Achillion Pharmaceuticals Inc Thiazole compounds and methods of use
WO2007034881A1 (ja) * 2005-09-22 2007-03-29 Dainippon Sumitomo Pharma Co., Ltd. 新規アデニン化合物
GB0610666D0 (en) 2006-05-30 2006-07-05 Glaxo Group Ltd Fluid dispenser
TW200843779A (en) 2007-02-19 2008-11-16 Smithkline Beecham Corp Compounds
DK2132209T3 (da) * 2007-03-19 2014-04-14 Astrazeneca Ab 9-substituerede 8-oxo-adeninforbindelser som modulatorer af tlr7 (toll-like receptor 7)
PE20091156A1 (es) * 2007-12-17 2009-09-03 Astrazeneca Ab Sales de (3-{[[3-(6-amino-2-butoxi-8-oxo-7,8-dihidro-9h-purin-9-il)propil](3-morfolin-4-ilpropil)amino]metil}fenil)acetato de metilo
US8777708B2 (en) 2008-06-27 2014-07-15 Microsoft Corporation Targeting control in a simulated environment
UA103195C2 (uk) * 2008-08-11 2013-09-25 Глаксосмитклайн Ллк Похідні пурину для застосування у лікуванні алергій, запальних та інфекційних захворювань

Also Published As

Publication number Publication date
MX2012009316A (es) 2012-09-12
KR20120135408A (ko) 2012-12-13
CA2786973C (en) 2018-04-10
BR112012018904A2 (pt) 2020-09-01
SMT201400196B (it) 2015-01-15
CA2786973A1 (en) 2011-08-18
AU2011214468A1 (en) 2012-08-09
JP2013519645A (ja) 2013-05-30
JP5922587B2 (ja) 2016-05-24
KR101773541B1 (ko) 2017-08-31
CN102753553B (zh) 2016-03-30
IL220845A (en) 2016-08-31
US20120308609A1 (en) 2012-12-06
DK2534149T3 (da) 2015-01-05
PL2534149T3 (pl) 2015-03-31
ES2525826T3 (es) 2014-12-30
RS53745B1 (sr) 2015-06-30
EA021048B1 (ru) 2015-03-31
EP2534149A1 (en) 2012-12-19
SG182471A1 (en) 2012-08-30
PT2534149E (pt) 2014-12-23
SI2534149T1 (sl) 2015-02-27
CN102753553A (zh) 2012-10-24
ZA201205995B (en) 2014-01-29
EA201290631A1 (ru) 2013-03-29
WO2011098452A1 (en) 2011-08-18
AU2011214468B2 (en) 2015-05-28
EP2534149B1 (en) 2014-10-15
US8703754B2 (en) 2014-04-22
ME01926B (me) 2015-05-20

Similar Documents

Publication Publication Date Title
HRP20141258T1 (hr) 6-amino-2-{[(1s)-1-metilbutil]oksi}-9-[5-(1-piperidinil)pentil]-7,9-dihidro-8h-purin-8-on maleat
JP2013519645A5 (enExample)
ME02274B (me) DERIVATI PURINA ZA UPOTREBU U LEČENJU ALERGIJSKIH, INFLAMATORNIH l INFEKTIVNIH BOLESTI
BR112014001798A2 (pt) compostos de tetraciclina 9-aminometila substituídos
BRPI0720667A8 (pt) Métodos de administração de vacina
HK1221646A1 (zh) 高剂量普利多匹定用於治疗亨廷顿舞蹈症的用途
HRP20171512T1 (hr) Derivati betulina
CA2925624C (en) Substituted nicotinimide inhibitors of btk and their preparation and use in the treatment of cancer, inflammation and autoimmune disease
HRP20191257T1 (hr) Farmaceutske formulacije koje sadrže 4-{(1r)-2-[(6-{2-[(2,6-diklorbenzil)oksi]etoksi}heksil)amino]-1-hidroksietil}-2-(hidroksimetil)fenol
HK1206246A1 (en) Use of high dose laquinimod for treating multiple sclerosis
WO2012007159A3 (en) Novel gastro-retentive dosage forms
RU2017112308A (ru) Композиции и способы для лечения бессонницы
NZ625592A (en) Compositions and methods for the treatment of hepatic diseases and disorders
EP2444103A4 (en) UTERUS COLON CANCER VACCINE
MX377175B (es) Solucion para inhalacion de tiotropio, administrada en forma nebulizada y el uso de la misma para tratar enfermedad pulmonar obstructiva crónica (epoc).
HRP20211749T1 (hr) Pentanske kiseline supstituirane pirolo-[2-3,b]pirimidin-piridinima za liječenje virusnih infekcija influencom
HRP20141063T1 (hr) Cjepivo protiv hpv
JP2011529475A5 (enExample)
EA200600854A1 (ru) Новые соли тиотропия, способ их получения, а также содержащие их лекарственные композиции
EA201201393A1 (ru) Ингалятор, разработанный для доставки лекарственного средства в виде сухого порошка
EA200600886A1 (ru) Способ получения солей тиотропия, соли тиотропия, а также содержащие их лекарственные композиции
CO6331429A2 (es) Derivados de 5-(4-metanosulfonil-fenil)-tiazol para el tratamiento de enfermedades inflamatorias agudas y cronicas
RU2017126153A (ru) Фармацевтическая комбинация
CN101244267A (zh) 一种增强微生物疫苗免疫原性的免疫制剂
RU2012116226A (ru) Бронхолитическое средство на основе простагландина